Optimisation of the safety and efficacy of protein kinase inhibitors using endogenous and dietary biomarkers [ 2016 - 2018 ]

Research Grant

Researchers: Prof Michael Sorich (Principal investigator) ,  A/Pr Michael Wiese ,  Dr Andrew Rowland ,  Prof Howard Gurney ,  Prof John Miners

Brief description Many new cancer medicines are part of the 'kinase inhibitor' group of drugs. Although these drugs are effective in treating a range of different cancers, opportunities remain to improve the effectiveness and safety by more intelligently deciding the dose of the drug that a specific individual should receive. The research aims to assess whether the levels of chemicals normally present in the blood of individuals being treated can be used to guide the best dose an individual should receive.

Funding Amount $AUD 395,205.95

Funding Scheme Project Grants

Notes Standard Project Grant